This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Sutent® (sunitinib malate) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Efficacy in mRCC

Experience that stands the test of time. ​​​​​​​

Mode Of Action (MOA) 

SUTENT is an inhibitor of multiple receptor tyrosine kinases (TKIs), including the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), which are expressed in many types of solid tumours and are thought to play a crucial role in angiogenesis.1

Dysregulation of the VEGF pathway is frequently associated with RCC, due to loss of function of the von Hippel-Lindau gene2 making mRCC a highly vascular tumour and underlying why the VEGF pathway continues to be a target in RCC.2

Sutent Video

Watch the mechanism of action video for SUTENT

Real World Data

In 2006:

  • SUTENT was approved for first-line mRCC, transforming the treatment landscape and pushing OS to over 2 years for the first time in the history of the disease3,4,9

Today:

  • SUTENT remains a standard of care in first-line mRCC10
  • Over 300,000 patients have been treated with SUTENT worldwide11
  • Real-world experience has demonstrated OS of over 30 months8

Motzer RJ, et al. Lancet Oncol 2019;20:1370–1385
Gore ME, et al. Br J Cancer 2015;113:12–19
Noize P, et al. Pharmacoepidemiol Drug Saf 2017;26:1561–1569.
Ruiz-Morales J, et al. Eur J Cancer 2016;65:102–108.
Lalani A, et al. Can Urol Assoc J 2017;11:112–117.
Motzer RJ, et al. J Clin Oncol 2009;27:3584–3590.
Motzer RJ, et al. N Engl J Med 2013;369:722–731.

Real-world experience with SUTENT® improves OS outcomes over time4-8

Motzer RJ, et al. 2009. 
Gore ME, et al. 2015. 
Ruiz-Morales JM, et al. 2016.
Noize P, et al. 2017. 
Lalani AA, et al. 2017.

Data taken from Motzer RJ, et al. 2009. Gore ME, et al. 2015. Ruiz-Morales JM, et al. 2016. Noize P, et al. 2017. Lalani AA, et al. 2017.

EAP, Expanded Access Programme. IMDC, International Metastatic Renal Cell Carcinoma Database Consortium. OS, overall survival. No cross-trial comparisons may be made since trials were conducted using different methodologies and at different time points. Final and investigator review analyses unless otherwise stated.​​​​​​​

*Clinical trial data.Data for MSKCC risk groups. Data for IMDC risk groups 

Safety

See all SUTENT Safety Information 

 View

AE : Adverse Event 
ESMO:  European Society for Medical Oncology 
IMDC : International Metastatic RCC Database Consortium 
IO : Immuno-Oncology 
mOS : Median Overall Survival 
mPFS : Median Progression-Free Survival 
mRCC : Metastatic Renal Cell Carcinoma 
NHS : National Health Service 
NICE : National Institute for Health and Care Excellence 
OS : Overall Survival 
PFS : Progression-Free Survival 
TKI : Tyrosine Kinase Inhibitor 
References
  1. Chow LQ and Eckhardt SG. J clin Oncol 2007;25:884-896.
  2. Rini BI, et al. lancet 2011;378(9807):1931-1939
  3. SUTENT® Summary of Product Characteristics. Available at: https://www.medicines.org.uk 
  4. Motzer RJ, et al. J Clin Oncol 2009;27:3584–3590.
  5. Gore ME, et al. Br J Cancer 2015;113:12–19.
  6. Morales JMR, et al. Eur J Cancer 2016;65:102–108.
  7. Noize P, et al. Pharmacoepidemiol Drug Saf 2017;36:1561–1569.
  8. Lalani AA, et al. Can Urol Assoc J 2017;11:112–117.
  9. Schmidinger M, et al. Ther Adv Urol 2012;4:253–265.
  10. Motzer RJ, et al. N Engl J Med 2013;369;722–731.
  11. Pfizer. Data on file.
PP-SUT-GBR-0666 March 2021

Safety​​​​​​

Indication

  • SUTENT (sunitinib malate) is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (mRCC) in adults.

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No